Delivery of Yersinia pestis antigens via Escherichia coli outer membrane vesicles offered improved protection against plague.

Autor: Tong Z; State Key Laboratory of Pathogen and Biosecurity, Academy of Military Medical Sciences, Beijing, China., Zhang X; State Key Laboratory of Pathogen and Biosecurity, Academy of Military Medical Sciences, Beijing, China.; Public Health School, Mudanjiang Medical University, Mudanjiang, China., Guo X; State Key Laboratory of Pathogen and Biosecurity, Academy of Military Medical Sciences, Beijing, China., Wu G; State Key Laboratory of Pathogen and Biosecurity, Academy of Military Medical Sciences, Beijing, China., Cao S; State Key Laboratory of Pathogen and Biosecurity, Academy of Military Medical Sciences, Beijing, China., Zhang Y; State Key Laboratory of Pathogen and Biosecurity, Academy of Military Medical Sciences, Beijing, China., Meng X; State Key Laboratory of Pathogen and Biosecurity, Academy of Military Medical Sciences, Beijing, China.; Public Health School, Mudanjiang Medical University, Mudanjiang, China., Wang T; State Key Laboratory of Pathogen and Biosecurity, Academy of Military Medical Sciences, Beijing, China., Wang Y; State Key Laboratory of Pathogen and Biosecurity, Academy of Military Medical Sciences, Beijing, China., Song Y; State Key Laboratory of Pathogen and Biosecurity, Academy of Military Medical Sciences, Beijing, China., Yang R; State Key Laboratory of Pathogen and Biosecurity, Academy of Military Medical Sciences, Beijing, China., Du Z; State Key Laboratory of Pathogen and Biosecurity, Academy of Military Medical Sciences, Beijing, China.
Jazyk: angličtina
Zdroj: MSphere [mSphere] 2024 Sep 25; Vol. 9 (9), pp. e0033024. Date of Electronic Publication: 2024 Aug 19.
DOI: 10.1128/msphere.00330-24
Abstrakt: Outer membrane vesicles (OMVs) from Gram-negative bacteria can be used as a vaccine platform to deliver heterologous antigens. Here, the major protective antigens of Yersinia pestis, F1 and LcrV, were fused either with the leader sequence or the transmembrane domain of the outer membrane protein A (OmpA), resulting in chimeric proteins OmpA-ls-F1V and OmpA 46-159 -F1V, respectively. We show that OmpA-ls-F1V and OmpA 46-159 -F1V can be successfully delivered into the lumen and membrane of the OMVs of Escherichia coli, respectively. Mutation of ompA but not tolR in E. coli enhanced the delivery efficiency of OmpA-ls-F1V into OMVs. The OmpA-ls-F1V protein comprises up to 20% of the total protein in OMVs derived from the ompA mutant (OMV dA -ALS-F1V), a proportion significantly higher than the 1% observed for OmpA 46-159 -F1V in OMVs produced by an ompA mutant that expresses OmpA46-159-F1V, referred to as OMV dA -LATM5-F1V. Intramuscular ( i.m .) immunization of mice with OMV dA -ALS-F1V induced significantly higher levels of serum anti-LcrV and anti-F1 IgG, and provided higher efficacy in protection against subcutaneous ( s.c. ) Y. pestis infection compared to OMV dA -LATM5-F1V and the purified recombinant F1V (rF1V) protein adsorbed to aluminum hydroxide. The three-dose i.m . immunization with OMV dA -ALS-F1V, administered at 14-day intervals, provides complete protection to mice against s.c. infection with 130 LD 50 of Y. pestis 201 and conferred 80% against intranasal ( i.n .) challenge with 11.4 LD 50 of Y. pestis 201. Taken together, our findings indicate that the engineered OMVs containing F1V fused with the leader sequence of OmpA provide significantly higher protection than rF1V against both s.c . and i.n . infection of Y. pestis and more balanced Th1/Th2 responses.IMPORTANCEThe two major protective antigens of Y. pestis , LcrV and F1, have demonstrated the ability to elicit systemic and local mucosal immune responses as subunit vaccines. However, these vaccines have failed to provide adequate protection against pneumonic plague in African green monkeys. Here, Y. pestis F1 and LcrV antigens were successfully incorporated into the lumen and the surface of the outer membrane vesicles (OMVs) of E. coli by fusion either with the leader sequence or the transmembrane domain of OmpA. We compared the humoral immune response elicited by these OMV formulations and their protective efficacy in mice against Y. pestis . Our results demonstrate that the plague OMV vaccine candidates can induce robust protective immunity against both s.c . and i.n. Y. pestis infections, surpassing the effectiveness of rF1V. In addition, immunization with OMVs generated a relatively balanced Th1/Th2 immune response compared to rF1V immunization. These findings underscore the potential of OMVs-based plague vaccines for further development.
Competing Interests: The authors declare no conflict of interest.
Databáze: MEDLINE
Externí odkaz: